证券代码：600538 证券简称：国发股份 公告编号：临2026-003 登录新浪财经APP 搜索【信披】查看更多考评等级 北海国发川山生物股份有限公司 关于大股东持有的公司部分股份被司法轮候冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ●重要内容提示: 朱蓉娟持有的公司无限售流通股1,784万股于2026年1月9日被广西壮族自治区南宁市青秀区人民法院司 法轮候冻结。 截至本公告披露日，朱蓉娟持有的公司2,100万股股份已全部被司法标记、司法冻结或轮候冻结，占公 司总股本的4.01%。 近日，北海国发川山生物股份有限公司（以下简称"公司"）通过中国证券登记结算有限公司上海分公司 的PROP系统查询获悉，公司大股东朱蓉娟持有的公司1,784万股无限售流通股于2026年1月9日被广西壮 族自治区南宁市青秀区人民法院司法轮候冻结。经与大股东朱蓉娟核实，现将司法轮候冻结的具体情况 公告如下： 一、股份被司法冻结的基本情况 ■ 二、大股东及其一致行动人股份累计被冻结/标记的情况 截至2026年1月9日，大股东及其一致行动人 ...

Core Insights - The animal health sector experienced a rise of 1.09% on January 13, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Stock Performance - Huisheng Biological (300871) closed at 25.06, up 8.39%, with a trading volume of 276,700 shares and a transaction value of 700 million [1] - Other notable performers included: - Qudongli (920275) at 65.6, up 3.99% [1] - Haili Biological (603718) at 6.66, up 1.99% [1] - Xianfeng Holdings (002141) at 3.77, up 1.34% [1] - Shunlian Biological (688098) at 9.78, up 1.03% [1] Capital Flow - The animal health sector saw a net inflow of 34.99 million from institutional investors, while retail investors contributed a net inflow of 30.94 million [2] - However, speculative funds experienced a net outflow of 65.94 million [2] Individual Stock Capital Flow - Major net inflows were observed in: - Biological Shares (600201) with a net inflow of 39.54 million [3] - Jinhe Biological (002688) with a net inflow of 13.45 million [3] - Xianfeng Holdings (002141) with a net inflow of 10.20 million [3] - Conversely, significant net outflows were noted in: - Biological Shares (600201) with a net outflow of 48.25 million from speculative funds [3] - Jinhe Biological (002688) with a net outflow of 1.46 million from retail investors [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●北海国发川山生物股份有限公司（以下简称"公司"）董事会于2026年1月11日收到公司非独立董事李勇 先生的书面辞任报告，因公司治理结构调整，李勇先生申请辞去公司第十一届董事会非独立董事的职 务。 ●公司第一届职工代表大会第二次会议选举李勇先生为公司第十一届董事会职工代表董事。 一、董事离任情况 （一）提前离任的基本情况 ■ 公司于2025年12月18日召开的2025年第三次临时股东大会审议通过了《关于取消监事会的议案》《关于 修订〈公司章程〉的议案》，根据修订后的《公司章程》的有关规定：公司董事会由9名董事组成，其 中职工代表董事的人数为1名。职工代表董事由公司职工通过职工代表大会、职工大会或者其他形式民 主选举产生。 公司于2026年1月12日召开了第一届职工代表大会第二次会议，经与会职工代表民主讨论与表决，同意 免去陈燕女士第十一届监事会职工代表监事职务，选举李勇先生（简历附后）为公司第十一届董事会职 工代表董事，任期自本次职工代表大会审议通过之日起至公司第 ...

证券代码：600538 证券简称：国发股份 公告编号：临2026-002 北海国发川山生物股份有限公司 关于公司董事离任暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 （二）离任对公司的影响 根据《中华人民共和国公司法》（以下简称"《公司法》"）《北海国发川山生物股份有限公司章程》 （以下简称"《公司章程》"）的相关规定，李勇先生辞去公司非独立董事职务不会导致公司董事会成员 人数低于法定最低人数，不影响公司董事会的正常运作，李勇先生的辞任报告自送达公司董事会之日起 生效。截至本公告披露日，李勇先生未持有公司股票，不存在应履行而未履行的公开承诺。辞任后，李 勇先生继续在公司及其控股子公司任职。 二、职工代表董事选举情况 公司于2025年12月18日召开的2025年第三次临时股东大会审议通过了《关于取消监事会的议案》《关于 修订〈公司章程〉的议案》，根据修订后的《公司章程》的有关规定：公司董事会由9名董事组成，其 中职工代表董事的人数为1名。职工代表董事由公司职工通过职工代表大会、职工大会或者其他形式民 ...

Macroeconomic Insights - The US unemployment rate fell to 4.4% in December, down from a revised 4.5% in November, indicating a temporary halt in concerns over job market deterioration[11] - The US manufacturing PMI declined while the services PMI increased, reflecting mixed economic signals[7] - Consumer confidence in the US continued to recover in January, with inflation expectations slightly rising[7] Market Trends - Risk assets generally rose in the week of January 2-9, 2026, with major economies' stock markets and commodity prices increasing[7] - The 10-year US Treasury yield rose by 5.7%, while domestic 10Y government bond futures prices fell by 0.1%[7] - The dollar index increased by 0.7%, with the USD/CNY exchange rate at 6.98, indicating a slight appreciation of the yuan[7] Sector Performance - The AI application sector is expected to see significant growth, with a projected compound annual growth rate (CAGR) of over 35% for the AI industry and over 63% for the large model market[23] - The consumer electronics sector, particularly smart glasses, is experiencing rapid growth, with a projected 110% year-on-year increase in global shipments in the first half of 2025[38] Investment Recommendations - It is advised to overweight A/H shares due to multiple factors supporting Chinese equity performance, including an expected expansion of the fiscal deficit and a more aggressive economic policy[18] - Gold is recommended for overweight allocation due to its strong resilience and safe-haven attributes amid rising geopolitical uncertainties[20] - The report suggests a cautious approach to oil investments, recommending a lower allocation due to expected price pressures from geopolitical events and US policy directions[20]

Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]

Investment Rating - The industry rating is "Recommended" [4] Core Views - The sentiment in the pork market has significantly improved, with a notable reduction in losses for pig farming. The average price of live pigs is currently 12.55 CNY/kg, remaining stable week-on-week. The number of breeding sows has decreased by 1.1% month-on-month and 2.1% year-on-year, indicating a steady adjustment in pig production capacity [2][12] - The Ministry of Agriculture and Rural Affairs has initiated a nationwide inspection of winter crop seeds to ensure safety for the upcoming spring and summer planting seasons. This includes a focus on key crops such as corn, rice, soybeans, cotton, and vegetables. The commercialization of genetically modified seeds is expected to accelerate, enhancing self-sufficiency rates for critical varieties [1][11] Summary by Sections Planting Industry Chain - The Ministry of Agriculture is conducting inspections to ensure seed quality and compliance, which is crucial for agricultural production safety. The emphasis on genetically modified technology is expected to revolutionize yield improvements, with companies like Beidahuang and Suqian Agricultural Development likely to benefit [1][11] Pig Farming - The average price of live pigs is 12.55 CNY/kg, with a slight increase in slaughter volume by 17.4% year-on-year. The market sentiment has improved significantly, with a reduction in losses for self-bred and purchased pig farming, indicating a potential for recovery in the sector. Recommended stocks include companies like Muyuan Foods and Wens Foodstuffs [2][12] Key Agricultural Product Data Tracking - Corn: The average price is 2353.51 CNY/ton, with a slight increase of 0.09% week-on-week. The international price is 5.21 USD/bushel, up 2.11% [26][27] - Wheat: The domestic average price is 2513.62 CNY/ton, down 0.09% week-on-week. The international price is 5.82 USD/bushel, down 0.13% [29][31] - Soybeans: The domestic average price is 4048.42 CNY/ton, up 0.63% week-on-week. The international price is 405.95 USD/ton, up 0.74% [39][43] - Cotton: The average price in Xinjiang is 15530.00 CNY/ton, up 0.84% week-on-week [45][49] Feed and Vitamin Prices - The average price of pig feed is 2.64 CNY/kg, with a week-on-week increase of 0.76%. The prices for chicken feed and egg-laying hen feed remain stable [52][54]

Core Insights - In the past five trading days (January 5 to January 9), 13 companies experienced significant shareholder increases, totaling 33.76 million shares and an aggregate increase amount of 402 million yuan [1] - During the same period, 163 companies had significant shareholder reductions, with a total reduction amount of 15.48 billion yuan [1] Summary by Category Shareholder Increases - Eight companies had increases exceeding 10 million yuan, with Wanrun Co., Ltd. leading at 7.50 million shares and an increase amount of 11.43 million yuan [1] - Tongji Technology followed with an increase of 5.62 million shares and 7.48 million yuan, while Aofei Data ranked third with an increase of 5.45 million yuan [1] - The distribution of increases showed that three companies were from the Growth Enterprise Market (GEM) and nine from the main board, with GEM increases totaling 7.41 million yuan and main board increases at 316 million yuan [1] Market Performance - Stocks with shareholder increases averaged a rise of 7.47% over the past five days, outperforming the Shanghai Composite Index during the same period [1] - Notable gainers included Aofei Data, with a rise of 23.58%, followed by Biological Shares at 15.46% and Hengshi Technology at 13.70% [1] - Conversely, Hengyi Petrochemical and Huamao Logistics experienced declines of 2.60% and 0.82%, respectively [1] Fund Flow - Among the stocks with shareholder increases, eight saw net inflows of main funds, with Biological Shares receiving the highest net inflow of 67 million yuan [2] - The companies with the largest net outflows included Huamao Logistics and Hengshi Technology, with outflows of 40 million yuan and 18 million yuan, respectively [2]

Group 1: Company Overview - The report focuses on Bio Co., Ltd. (600201), highlighting its potential breakthrough with the African Swine Fever vaccine, which is expected to reshape its competitive advantage and growth momentum [3][4]. - The recommendation logic emphasizes the company's strong R&D barriers, rich product pipeline, and the recent clinical approval of the ASF vaccine, which could become the main growth driver over the next 3-5 years [3][4]. Group 2: Financial Projections - Projected revenues for Bio Co., Ltd. from 2025 to 2027 are estimated at 1,603.76 million, 2,035.36 million, and 2,520.85 million yuan, with year-on-year growth rates of 27.74%, 26.91%, and 24.85% respectively [4]. - The net profit attributable to the parent company is forecasted to be 303.45 million, 397.65 million, and 491.31 million yuan for the same period, with growth rates of 178.44%, 31.04%, and 23.55% respectively [4]. Group 3: Catalysts and Drivers - Key catalysts include breakthroughs in the ASF vaccine development and advancements in the mRNA vaccine for feline infectious peritonitis [4]. - The driving factors for growth are the leading progress in ASF vaccine development, a solid position in foot-and-mouth disease, rapid expansion in the pet sector, and ongoing overseas market development [3][4]. Group 4: Market Position and Strategy - The company is expected to exceed performance expectations due to the clinical approval of the ASF vaccine, diversified product launches, and rapid overseas market expansion [3]. - The strategy includes leveraging marketing support, online channel development, and international market penetration to drive revenue growth [3].

Core Logic - The company has strong R&D barriers and a rich pipeline of new products, with the non-epidemic vaccine having received clinical approval, which could become the largest growth engine in the next 3-5 years if progress is smooth [1] Industry Dynamics - The animal health sector is expected to maintain a volume increase but price decrease trend due to weak recovery in the breeding industry and profit compression, with overall gross margins declining amid intense competition and product homogenization [2] Product Development - The company is a leader in the foot-and-mouth disease vaccine market, transitioning its core product logic to the subunit non-epidemic vaccine, which has a broad market potential. The market size is expected to reach 1.75 billion yuan in the first year and 3.5 billion yuan in the second year post-launch. The subunit non-epidemic vaccine is set to enter clinical trials in July 2025, with potential revenue contributions starting from late 2027 to early 2028 [3] Marketing Strategy - The company focuses on "big products + big clients," providing comprehensive solutions and building a multi-layered marketing system. Online and overseas market expansions are showing initial success, with pet direct sales increasing over fourfold year-on-year in the first half of 2025. The company has registered sales of foot-and-mouth products in countries like Pakistan and Vietnam, with plans for deeper market penetration in Mongolia and Central Asia [4] Financial Forecast - The company expects overall revenue of 1.604 billion, 2.035 billion, and 2.521 billion yuan for 2025-2027, with year-on-year growth rates of 27.74%, 26.91%, and 23.85%. The net profit attributable to shareholders is projected to be 304 million, 398 million, and 491 million yuan, with growth rates of 178.44%, 31.04%, and 23.55%, corresponding to P/E ratios of 64, 49, and 39 times [5]